A pinch of salt - A podcast by ERA

For decades, treating IgA nephropathy meant looking thoughtful while saying "let's optimise supportive care and monitor closely." Not anymore. We've gone from one road to a full therapeutic roundabout, and nobody wants the wrong exit. Hugo Diniz welcomes Vlado Perkovic to navigate the new era: anti-APRIL and anti-BAFF agents, the VISIONARY and ORIGIN data, and the 2025 KDIGO framework. Are we finally switching off the disease at its source, or just admiring another elegant proteinuria curve? Vlado helps us separate evidence from excitement, and hype from hope. A new episode of A pinch of salt.

This is “A pinch of salt” live from the 63rd ERA Congress! Recorded straight out of a packed Clyde Plenary Room: six trials, ninety minutes! Hugo Diniz, the new podcast host, brings you rapid-fire expert commentary with two titans of European nephrology, Alberto Ortiz and Danilo Fliser. On the menu — a brand-new CKD drug class (nurandociguat), what patients actually feel on semaglutide (FLOW sub-analysis), two IgA nephropathy therapies going long-term (atrasentan and iptacopan), anticoagulation in advanced kidney disease (TRACK), and the first randomised trial of dialysis versus conservative care. An episode you just can’t miss!

Are we all about to be replaced by chatbots? Probably not — but is there a risk of Gen-AI acute tubular necrosis for those who don't adapt? Hugo Diniz is joined by Wisit Cheungpasitporn to demystify what generative AI can actually do, expose what it definitely can't (yet), and make it approachable for every working nephrologist. From automating those soul-crushing clinic notes to navigating the constant flow of new evidence, "vibe coding" your own tools, and the dark side of energy use and patient privacy. AI may not replace your clinical judgment anytime soon — but it might just cure our chronic administrative disease.

In this episode Maria Jose Soler Romeo joins us to break down the shifting landscape of MRAs and Aldosterone Synthase Inhibition. We’ll cover the central role of aldosterone as a central culprit in inflammation and renal fibrosis, how the rise of non-steroidal MRAs is helping clinicians bypass traditional roadblocks like hyperkalemia and the future of slowing CKD progression through precision medicine.